Effective Oral Administration of an Antitumorigenic Nanoformulated Titanium Complex

Gilad Nahari, Ori Braitbard, Liraz Larush, Jacob Hochman*, Edit Y. Tshuva*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Abstract: Orally administered anticancer drugs facilitate treatment, but the acidic conditions in the stomach often challenge their availability. PhenolaTi is a TiIV-based nontoxic anticancer drug with marked in-vivo efficacy. We report that nanoformulation protects phenolaTi from decomposition in stomach-like conditions. This is evidenced by similar NMR characteristics and similar in-vitro cytotoxicity toward murine (CT-26) and human (HT-29) colon cancer cells before and after incubation of nanoformulated phenolaTi (phenolaTi-F) at pH 2, unlike results with the unformulated form of the complex. Furthermore, administration of phenolaTi-F in animal drinking water revealed a notable inhibition of tumor growth in Balb/c and immune-deficient (Nude) mice inoculated with CT-26 and HT-29 cells, respectively. In-vivo efficacy was at least similar to that of the corresponding intraperitoneal treatment with phenolaTi-F and the clinically employed oral drug, capecitabine. No body weight loss or clinical signs of toxicity were evident in the phenolaTi-F-treated animals. These findings demonstrate a new convenient mode of cancer treatment through oral administration by safe titanium-based drugs.

Original languageAmerican English
Pages (from-to)108-112
Number of pages5
Issue number1
StatePublished - 8 Jan 2021

Bibliographical note

Publisher Copyright:
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim


  • antitumor agents
  • metallodrug
  • nanoformulations
  • oral administration
  • titanium


Dive into the research topics of 'Effective Oral Administration of an Antitumorigenic Nanoformulated Titanium Complex'. Together they form a unique fingerprint.

Cite this